- cafead Dec 16, 2018 at 12:42: AM
via FDA approved a BLA for Herceptin biosimilar Herzuma trastuzumab-pkrb from Celltrion Inc. (KOSDAQ:068270) to treat HER2-positive breast cancer.
article source
article source
-
Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page
FDA approves Celltrion's Herceptin biosimilar
- Thread starter cafead
- Start date
Similar threads